“Less Radical” podcast: Resistance to change, a data scandal

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

“Less Radical” is the story of Bernie Fisher, the surgeon-scientist who not only revolutionized breast cancer treatment, but also fundamentally changed the way we understand all cancers. 

He was an underdog from the start—a Jewish kid from Pittsburgh who had to make it past antisemitic quotas to get into med school. 

And the thanks he received for his discoveries? 

A performative, misguided Congressional hearing that destroyed his reputation and haunted him until his death.

Over six episodes—including a bonus episode—radiation oncologist Stacy Wentworth takes you into operating rooms, through the halls of Congress, and into the labs where breakthrough cancer treatments were not only developed, but discovered.

On Oct. 17, “Less Radical” was named one of the best podcasts of the week by The Guardian:

Dr. Bernie Fisher was pivotal in improving the way breast cancer patients are treated—women might still be having disfiguring surgery without his work. Here, Dr. Stacy Wentworth takes us from the operating room to the White House to show how Fisher, the women’s movement, and science radically changed breast cancer treatment. 

–Hollie Richardson

Wentworth and “Less Radical” producer Melody Rowell discussed the podcast on A1, a daily news and conversation program produced by WAMU, the NPR station serving the Washington, DC area. 

“The Study Culture Podcast,” also produced by Rowell, invited Wentworth to discuss “Less Radical” in the episode “Why Are We So Weird About Cancer?” 

The final two episodes of “Less Radical” are now available, and all six episodes can be found on the Cancer History Project.

Episode 4: Immovable Objects and Unstoppable Forces
By “Less Radical,” Oct. 21, 2024

We return to Washington, D.C. In the fall of 1974, the results of Bernie’s clinical trials promise to change the treatment of breast cancer forever… if only it were that easy.

Episode 5: Bureaucrats, Administrators, and Politicians
By “Less Radical,” Nov. 1, 2024

When a colleague’s misconduct is discovered, Fisher is forced to resign from the NSABP and becomes the subject of a Congressional investigation. As the walls close in, Fisher fights back. He spends the rest of his life trying to restore his reputation.


This column features the latest posts to the Cancer History Project by our growing list of contributors

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available. 

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj, or follow our podcast.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

YOU MAY BE INTERESTED IN

Genentech announced positive topline results from the overall survival analysis of the phase III INAVO120 study investigating Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant for people with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. 
FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by the FDA approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
A new statistical tool that combines multiple clinical and pathologic factors with a patient’s 21-gene Oncotype DX Breast Recurrence Score result provides more accurate estimates about that patient’s breast cancer prognosis and their potential benefit from chemotherapy than either the Recurrence Score result or clinical factors alone, a SWOG Cancer Research study found.
Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history. 
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine, also referred to as T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login